Neurocrine Biosciences, Inc. (NBIX) announced on Monday that recent findings from the Phase 3 KINECT-3 and KINECT-4 studies indicate significant and comprehensive patient improvements with Ingrezza in the treatment of tardive dyskinesia.
Tardive dyskinesia is a neurological disorder characterized by repetitive, involuntary movements.
The results, which were presented at the 2024 Psych Congress, include data from over 300 patients.
Ingrezza received its initial approval for the treatment of tardive dyskinesia in 2017.
“These comprehensive data from both clinical studies and real-world patient observations represent one of the most extensive evaluations of the impact of treating tardive dyskinesia with INGREZZA. They demonstrate substantial improvements in outcomes valued by both patients and clinicians," stated Eiry W. Roberts, Chief Medical Officer of Neurocrine Biosciences.
